Axq Capital, LP Sage Therapeutics, Inc. Transaction History

Axq Capital, LP

$417 Billion
Q1 2024

A detailed history of Axq Capital, LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 10,570 shares of SAGE stock, worth $113,944. This represents 0.05% of its overall portfolio holdings.

Number of Shares

10,570

Holding current value

$113,944

% of portfolio

0.05%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 14, 2024	BUY	$18.62 - $26.95 $196,813 - $284,861	10,570 New	10,570 $198 Million
Q1 2023 May 10, 2023	BUY	$37.27 - $46.57 $537,135 - $671,166	14,412 New	14,412 $605 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

Vanguard Group Inc Valley Forge, PA

5.75M
Shares

$62 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.48M
Shares

$59.1 Million
1.65% of portfolio
Black Rock Inc. New York, NY

4.89M
Shares

$52.7 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

4.75M
Shares

$51.2 Million
0.02% of portfolio
State Street Corp Boston, MA

4.49M
Shares

$48.5 Million
0.0% of portfolio

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.

Account